FDA rejects Teva’s request to block Watson’s generic Seasonique
PARSIPPANY, N.J. — A federal court has rejected Teva Pharmaceutical Industries’ efforts to prevent Watson from launching a generic version of one of its drugs, Watson said Friday.
The U.S. District Court for the District of Nevada denied Duramed Pharmaceuticals’ request for an injunction to keep Watson’s generic version of the contraceptive Seasonique (levonorgestrel and ethinyl estradiol 0.15 mg/0.03 mg) and ethinyl estradiol 0.01 mg from being launched.
Seasonique is made by Teva Women’s Health, the successor of Duramed.
Armada inks deal with Emdeon
FLORHAM PARK, N.J. — Armada Health Care and Emdeon have entered an agreement to support prior authorization management through Armada’s ReachRx suite of services, Armada said.
Emdeon — which contracts with pharmacies and their service providers to simplify and improve end-to-end prescription processes — will use its network to support and enhance prior authorization management for Armada member pharmacies, automating data exchange in real-time, and aligning the solutions with standard pharmacy workflow. Armada said those services would enhance its ability to offer member pharmacies "a turnkey solution to managing time-consuming prior authorizations both quickly and effectively."
According to Armada, the inability of pharmacies to provide effective prior authorization services resulted in patient attrition and lost revenue, because they could not handle the submission of clinical documentation and extensive follow-up with prescribers, unless they had necessary staffing and resources.
Armada’s prior authorization services include automatic transfer of claims data to the Armada platform, status follow-up with prescriber and payer, co-pay assistance information, real-time status updates via the Armada Web portal and full HIPAA compliance.
Watson’s nabumetone tablets get FDA OK
PARSIPPANY, N.J. — The Food and Drug Administration has approved a drug for arthritis made by Watson Pharmaceuticals, Watson said Friday.
The drug maker announced the approval of nabumetone tablets in the 500-mg and 750-mg strength. The drug is used to treat signs and symptoms of rheumatoid arthritis and osteoarthritis.
Nabumetone had sales of $58 million during the 12-month period ended in April, according to IMS Health.